IPA, InterSystems , a creative data technology provider that helps customers solve their most critical challenges in scalability, interoperability and speed, and ImmunoPrecise Antibodies Ltd (IPA) (NASDAQ: IPA) an artificial intelligence-driven biotherapeutic research and technology company, are pleased to announce the formation of a historic partnership. This collaboration, which integrates the new vector search functionality of the InterSystems IRIS ® data platform with the LENS ai platform from IPA subsidiary BioStrand, sets a new standard for AI-based applications in healthcare and life sciences.
This collaboration represents a major technological advancement that will enable the healthcare and life sciences sectors to meet the challenges associated with increasing volumes of data. Against the backdrop of a global AI market expected to be worth more than $1.3 trillion by 2032 , the collaboration between InterSystems and IPA highlights both companies’ commitment to innovation, excellence and development of solutions that not only meet the current needs of the healthcare and life sciences sectors, but anticipate future challenges by providing highly anticipated additional solutions and developments, while vector research and LENS ai is redefining the interaction between data and AI-driven applications in healthcare and life sciences.
Also Read: Intelligencia AI, HealthTech company, appoints the president of its Scientific Advisory Committee
“As the latest addition to the InterSystems IRIS data platform, vector research has helped supercharge the identification and creation of new drug compounds, significantly reducing the time between R&D and commercialization,” said Scott Gnau, Head of Global Data Platforms, InterSystems. “We look forward to seeing how vector search within the InterSystems IRIS platform will enable other developers to build additional AI applications on our platform.” »
“By combining InterSystem’s vector search with IPA’s LENS ai , we provide life sciences developers and researchers with unparalleled tools to extract value and insights from complex data sets, advancing the potential of AI across all applications in the healthcare and life sciences sectors,” said Dr. Dirk Van Hyfte, Co-Founder and Chief Innovation Officer, BioStrand. “We are at the dawn of a new era of AI-driven applications, where the integration of sophisticated data analysis tools like vector search and the deep biological insights provided by LENS ai can lead to revolutionary advances in patient care and treatment methods.
SOURCE: Businesswire